Last updated: May 12, 2025
Sponsor: Massachusetts General Hospital
Overall Status: Active - Recruiting
Phase
2
Condition
Noncancerous Growth
Neoplasms
Treatment
Indocyanine green
SPY-PHI
Clinical Study ID
NCT04752137
2020P003481
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All patients 18 years of age or older who present to Massachusetts General HospitalDepartment of Orthopaedic Surgery with a benign or malignant bone or soft tissuemass that is consented for surgery during the study period.
Exclusion
Exclusion Criteria:
Pregnant or nursing patients
Patients with previously known anaphylaxis to IV contrast or iodine (other allergiesmay be considered on a case-by-case basis)
Patients in renal failure who are not cleared for ICG administration by theirprimary physician or oncologist
Study Design
Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Indocyanine green
Phase: 2
Study Start date:
May 25, 2022
Estimated Completion Date:
October 01, 2026
Study Description
Connect with a study center
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.